POST MARKETING STUDY OF THE ELIXIR DESyne NOVOLIMUS ELUTING CORONARY STENT SYSTEM AND THE DESyne BD NOVOLIMUS ELUTING CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

Trial Profile

POST MARKETING STUDY OF THE ELIXIR DESyne NOVOLIMUS ELUTING CORONARY STENT SYSTEM AND THE DESyne BD NOVOLIMUS ELUTING CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Novolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms EXCELLA PMCF
  • Sponsors Elixir Medical Corporation
  • Most Recent Events

    • 07 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
    • 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 02 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top